Clinical Trial

Disease: Solid Tumors, (NCT04551885)

Disease info:

A solid tumour is an abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumours may be benign (not cancer), or malignant (cancer). Solid tumour types are named according to the type of cell they originate from. Examples of solid tumours are sarcomas, carcinomas, and lymphomas. Leukaemias (cancers of the blood) generally do not form solid tumours. 

The word tumour does not always imply cancer. In discussing tumours that are malignant (cancerous), however, the term solid tumour is used to distinguish between a localised mass of tissue and leukaemia.

Frequency:
Excluding non-melanoma skin cancers, over 2 million new cancer cases are expected to be diagnosed in the US in 2025.
Official title:
A Phase I, Open-Label, Multicenter Study of FT516 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
Who:
Partners:
Locations:

United States, Minnesota 
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States, 55455

United States, New Jersey 
Hackensack University Medical Center/John Theurer Cancer Center, Hackensack, New Jersey, United States, 07601

United States, Texas 
MD Anderson Cancer Center, Houston, Texas, United States, 77030

Study start:
Sep. 7, 2020
Enrollment:
12 participants
Gene editing method:
Type of edit:
Gene enhancement
Gene:
CD16
Delivery method:
- Ex-vivo
Note:
This study was terminated by the Sponsor.
Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Terminated

Description

This is a Phase 1 dose-finding study of FT-516 in combination with monoclonal antibodies in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Last updated: Feb. 24, 2025
close
Search CRISPR Medicine